Chimerix Awarded BARDA Contract for Development of Antiviral CMX001 Countermeasure Against Smallpox
According to the announcement, Chimerix, Inc, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for advanced development of its antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release.
Excerpt:
"RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2011 /PRNewswire/ --
Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Chimerix's broad spectrum antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release.
CMX001 is a potential dual-use therapeutic with evidence of antiviral activity against all five families of double-stranded DNA (dsDNA) viruses that cause morbidity and mortality in humans, including smallpox. Under the terms of the BARDA contract, Chimerix will receive committed funding of $24.8 million during the first year with subsequent option periods that, if completed, would bring the total contract value to $81.1 million.
The funding from BARDA builds upon the $37 million Chimerix previously received from the National Institute of Allergy and Infectious Diseases (NIAID) for development of CMX001 for smallpox, in addition to substantial private investment from top-tier venture capital firms for the development of CMX001 as a treatment for other life-threatening infections such as adenovirus and cytomegalovirus.
As part of progressing the clinical and non-clinical development of CMX001 for the smallpox indication, the BARDA contract will also support expanded human safety trials and the recently initiated CMX001-350 multicenter, open-label clinical study of CMX001 for the treatment of twelve life-threatening or serious conditions caused by dsDNA viruses. This represents Chimerix's first contract with BARDA and will position CMX001 for possible procurement as a medical countermeasure for the Strategic National Stockpile."
Read More at http://www.prnewswire.com/news-releases/chimerix-awarded-barda-contract-for-advanced-development-of-broad-spectrum-antiviral-cmx001-as-medical-countermeasure-against-smallpox-116318154.html
No comments:
Post a Comment